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Abstract
MicroRNAs (miRNAs) contribute to cancer initiation and progression by silencing the expression of their target genes,
causing either mRNA molecule degradation or translational inhibition. Intraductal epithelial proliferations of the breast are
histologically and clinically classified into normal, atypical ductal hyperplasia (ADH), ductal carcinoma in situ (DCIS) and
invasive ductal carcinoma (IDC). To better understand the progression of ductal breast cancer development, we attempt to
identify deregulated miRNAs in this process using Formalin-Fixed, Paraffin-Embedded (FFPE) tissues from breast cancer
patients. Following tissue microdissection, we obtained 8 normal, 4 ADH, 6 DCIS and 7 IDC samples, which were subject to
RNA isolation and miRNA expression profiling analysis. We found that miR-21, miR-200b/c, miR-141, and miR-183 were
consistently up-regulated in ADH, DCIS and IDC compared to normal, while miR-557 was uniquely down-regulated in DCIS.
Interestingly, the most significant miRNA deregulations occurred during the transition from normal to ADH. However, the
data did not reveal a step-wise miRNA alteration among discrete steps along tumor progression, which is in accordance
with previous reports of mRNA profiling of different stages of breast cancer. Furthermore, the expression of MSH2 and
SMAD7, two important molecules involving TGF-b pathway, was restored following miR-21 knockdown in both MCF-7 and
Hs578T breast cancer cells. In this study, we have not only identified a number of potential candidate miRNAs for breast
cancer, but also found that deregulation of miRNA expression during breast tumorigenesis might be an early event since it
occurred significantly during normal to ADH transition. Consequently, we have demonstrated the feasibility of miRNA
expression profiling analysis using archived FFPE tissues, typically with rich clinical information, as a means of miRNA
biomarker discovery.
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Introduction
Among women, breast cancer is the second most notorious
cause of cancer deaths after lung cancer, and the most prevalent
form of cancer, excluding skin cancer. According to the American
Cancer Society, approximately 230,480 new cases of invasive
breast cancer are expected to be diagnosed, as well as an estimated
57,650 additional cases of in situ tumor in the United States in
2011, and about 39,520 women are expected to die from the
malignance. Current prognosis and treatment results vary
depending upon the stage and size of the tumor; Ten-year
disease-free survival rates vary from 98% to 10%. Early detection
of the preneoplastic lesion remains the key to improving patient
outcomes and survival, reducing patient suffering and costs.
Therefore, more accurate and powerful diagnostic and predictive
tools are needed for early non-invasive breast cancer.
Current concepts regard intraductal epithelial proliferations of
breast as a heterogeneous disease composed of various types of
neoplasms and subpopulations (e.g. hyperplasia, atypical hyper-
plasia, DCIS) in different areas of the same tumor. Thus, they
differ in their potential to progress and metastasize. It is reasonable
to postulate that there will be significant gene expression
differences among different sub-populations in the same tumor
tissue, all of which undergo hypoxia and hormone stimulation
within the same microenvironment. However, most breast cancers
would receive adjuvant chemotherapy and/or other interventions
after diagnosis. Therefore it is hard to determine whether or not
non-metastatic tumors were impacted by aggressive treatment,
thus challenging the representativeness of the sampling.
PLOS ONE | www.plosone.org 1 January 2013 | Volume 8 | Issue 1 | e54213
Archival collections of Formalin-Fixed, Paraffin-Embedded
(FFPE) tissues, linked to clinical databases, provide a rich and
efficient resource for biological insight compared to collections of
fresh frozen tissues. Because biomarkers developed from FFPE
samples could be more rapidly translated into clinical practice,
FFPE tissues can be an invaluable tool for biomarker discovery
and validation [1]. The formalin fixation process allows for
permanent preservation of the architecture of the tissue in optimal
histological condition and easy long-term storage. Unfortunately,
this process also compromises the yield, quality, and integrity of
the nucleic acids through enzymatic and chemical degradation,
extensive cross-linking with proteins and various chemical
modifications [2] [3]. miRNAs, partially due to their size, are
potentially more robust to FFPE-dependent degradation than
mRNAs. Therefore miRNAs could be a viable alternative for
expression profiling. Furthermore, it has been demonstrated in
multiple studies that miRNAs are minimally affected by FFPE
treatment, as isolated miRNAs displayed reliable expression levels
as compared to frozen tissue samples [4] [5] [6] [7].
Although extensive research on molecular mechanisms involved
in breast cancer has been done recently, challenges still prevail in
the early diagnosis and management of breast cancer patients,
such as unpredictable response and development of resistance to
adjuvant therapies. miRNAs, as regulators of protein-coding
genes, could serve as novel diagnostic and prognostic candidates,
and thus as potential therapeutic targets. Recent studies have
indicated that circulating miRNAs may serve as minimally
invasive biomarkers for cancer diagnosis [8]. Since the deregula-
tion of miRNA in breast cancer was first reported in 2005 [9],
there have been many studies on the expression of various
miRNAs and their roles in breast cancer (Table 1). miRNA
profiling studies have led to the identification of miRNAs that are
aberrantly expressed in human breast cancer, with miR-10b, miR-
125b and miR-145 being down-regulated and miR-21 and 155
being up-regulated. Tumor formation may arise from miRNA
deregulation. Iorio et al. [9] identified 29 miRNAs that were
differentially expressed in breast cancer tissue compared to normal
tissue, and a further set of 15 miRNAs that could be used to
discriminate between tumor from normal cells. In addition,
miRNA expression has been correlated with biopathological
features such as ER and PR expression (miR-30) as well as tumor
stages (miR-213 and miR-203). Differential expression of several let-
7 isoforms was associated with PR status (let-7c), lymph node
metastasis (let-7f-1, let-7a-3, let-7a- 2), or high proliferation index
(let-7c, let-7d) in tumor samples. Mattie et al. identified unique sets
of miRNAs associated with breast cancers currently defined by
their HER2 or ER/PR status [10]. miRNAs exert their function
by directly targeting downstream genes and their associated
pathways with sequence preference on mRNA seed sequence [11].
They can function as either tumor suppressors [12–15] or
oncogenes (sometimes refer to as oncomir) [16–23]. Thus, tumor
formation, progression and metastasis may arise from a suppres-
sion of tumor suppressor miRNAs and/or overexpression of an
oncogenic miRNA. We attempt to profile miRNA expression
patterns to identify potential biomarkers for the diagnosis of pre-
invasive breast lesions.
In this study, we identified 8-patient FFPE blocks that contain
multiple components of the tissue, such as histologically normal
epithelial, ADH, DCIS and/or invasive tumor cells. We micro-
dissected each sample as described earlier [24] and collected tissue
samples. Total RNAs were isolated for miRNA microarray
analysis. We observed different miRNA expression patterns
between different subgroups, which may allow us to identify
unique miRNA signatures for each neoplasm type. After
expression profiling, we obtained a list of miRNAs based on
representatives from different clusters for discrete stages of
classification: statistically significant expression levels were identi-
fied as from the 50th percentile and upward; comparison to prior
publications demonstrating their functional implications in breast
cancer or other tumors; application of commercially available
qRT-PCR assays for validation. To validate our findings, we
performed a second microarray expression profiling assay on 16
patients with definitive diagnosis of normal, ADH, DCIS and IDC
cases. Using the same criteria as described above, we obtained a
unique list of miRNAs that are differentially expressed. Then, we
extracted overlapping miRNAs from both studies. The expression
of these miRNAs was further verified by TaqMan qRT-PCR. We
identified molecular targets of these miRNAs using the target
prediction analysis by three different algorithms, such as
TargetScan 6.0, Diana microT 3.0 and miRanda (micro-
RNA.org). As a proof of principle, we used anti-miR-21 oligo to
transfect MCF-7 and Hs578T cells, and as predicted, we observed
restoration of MSH2 and SMAD7 expression levels following
miR-21 knock-down. MSH2 is a component of the post-replicative
DNA mismatch repair system (MMR), frequently mutated in
hereditary nonpolyposis colon cancer (HNPCC). SMAD7 is an
antagonist of signaling by the TGF-b1 superfamily members and
has been shown to inhibit TGF-b and activin signaling by
associating with their receptors thus preventing SMAD2 access.
Results
Laser Capture Microdissection (LCM) Approach and FFPE
total RNA Isolation
Breast cancer is a heterogeneous disease. To isolate the different
components of the premalignant breast tissue during the breast
cancer progression, we applied laser capture microdissection on 8
patient FFPE samples. Components of ADH, DCIS and IDC were
collected when available in addition to the adjacent normal
epithelium cells from all 8 patients. As expected, not all FFPE
samples contain all lesion components (Table 1).
The ABI RecoverAllTM Total Nucleic Acid Isolation Kit for
FFPE Tissues kits was used to isolate total RNA from the
microdissected FFPE tissue following the protocol described in the
Materials and Methods section. We routinely obtained more than
Table 1. Microdissected samples from breast cancer FFPE
blocks.
Patients Lesions
NORMAL ADH DCIS IDC
A A1* X A3 A4
B B1 B2 B3 B4
C C1 X C3 C4
D D1 D2 D3 X
E E1 E2 X E4
F F1 X F3 F4
G G1 G2 X G4
H H1 X X H4
*The letters (A, B, C …) represent each patient and the numbers, 1, 2, 3, 4
indicate ‘‘Normal’’, ‘‘ADH’’, ‘‘DCIS’’, ‘‘IDC’’ respectively in each patient’s FFPE
tissue. ‘‘X’’ means that no histological samples were obtained from an individual
FFPE sample.
doi:10.1371/journal.pone.0054213.t001
Deregulated miRNAs in Breast Cancer
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50 mg of total RNA from 4,5 15 mm thick sections, with an OD
260/280 ratio<2.0 and RIN (RNA Integrity Number) between
2.1,2.4. The low RIN was expected due to the nature of FFPE
fixation. However, it seems it has minimal adverse impact on
miRNA analysis.
MicroRNA Expression Comparisons in Early Breast Cancer
Using Agilent miRNA microarray technology, we profiled 24
LCM samples from 8 FFPE blocks, including 8 Normal, 4 ADH, 5
DCIS, and 7 IDC samples (Table 1). Sample D3 (DCIS sample
from Patient D), was excluded for robust statistical analysis due to
its failure to pass quality control. For unpaired analysis, miRNA
microarray expression profiling was also performed on an
additional 16 samples with clear clinical diagnoses without
subjecting them to LCM.
We first performed paired comparisons with patient-matched
histological types: ADH vs. Normal, DCIS vs. Normal, IDC vs.
Normal and IDC vs. DCIS, by using the t-test module in the
GeneSpring GX. Lists of differentially expressed miRNA candi-
dates with statistical significance (p,=0.05) are shown in Table 2.
Differentially expressed miRNAs with p,0.05 and fold change of
2.0 or above were verified by real-time PCR. Four miRNAs (miR-
21, miR-183, miR-200c and miR-200b) were significantly up-
regulated when comparing ADH vs. normal. miR-21 has been
well documented as an oncogene, while miR-200c/b are reported
as biomarkers for primary hepatocellular carcinoma [25] and
miR-200c as an independent prognostic factor in pancreatic
cancer [26]. Most interestingly, when comparing DCIS vs.
normal, we found 53 significantly changed miRNAs, including
miR-195, which is a potential biomarker for noninvasive and early
stage breast cancer in blood testing [27], and shows differential
expression between DCIS and normal cells [28]. Comparing IDC
and normal, miR-933, miR-141 and miR-96 were found to be
altered significantly.
Our unpaired microarray analysis from the second set of
samples identified 74 miRNAs that were differentially expressed
when comparing ADH to Normal, whereas DCIS and IDC
showed no significance in miRNAs alteration (Supplementary 2).
This is agreeable to our paired t-test analysis, which also shows
more altered miRNAs in normal to ADH transition. Additionally,
most of the miRNA deregulations (6 out of 9) that occurred in the
transition of Normal-ADH were also observed in later stages.
Taken together, the comparison results of the paired test indicate
that miRNA alterations are more significant during the Normal-
ADH transition than DCIS-IDC transition, and these alterations
can be maintained into later stages, a report which has been
confirmed by other investigations [29]. The most significant
miRNA expression changes occurred at the early tumor initiation
stage, suggesting that these miRNAs may serve as biomarkers for
early breast cancer detection and management.
Unsupervised Clustering on Different Clinicopathologic
Samples with all Detected miRNAs
It is widely believed that breast cancer initiates from the
premalignant ADH stage and then cumulates into the potentially
lethal IDC stage in a linear model. Therefore it is rational for us to
hypothesize that there are unique stepwise broad-wide miRNA
alterations for each stage transition. In other words, discrete
pathological stages of early stage breast cancer could have broad-
wide miRNA expression signatures. To pursue this hypothesis,
unsupervised hierarchical clustering was carried on 23 distinct
tumor stage samples and also on all detected miRNAs on the
arrays using Euclid correlation and centroid linkage. However,
after hierarchical clustering, we failed to readily find distinct
clusters separated by different stages as expected. Instead,
asynchronous stages from the same patient were shown to cluster
more closely to each other than to their peer-stages from different
patients (Fig. 1). This seems to be consistent with mRNA
expression profiling in the progression of human breast cancer
as previously reported [29]. This finding is also reasonable as the
Table 2. A representative list of deregulated miRNA entities
during the breast lesion transition.
Comparisons miRNA IDs p value Regulation
ADH vs. Normal hsa-miR-1275 0.011393113 DOWN
hsa-miR-638 0.021915715 DOWN
hsa-miR-572 0.02500332 DOWN
hsa-miR-671-5p 0.025993915 DOWN
hsa-miR-21 0.03355437 UP
hsa-miR-200b 0.039687086 UP
hsa-miR-15b 0.04428858 UP
hsa-miR-183 0.044314582 UP
hsa-miR-30d 0.049228158 UP
DCIS vs. Normal hsa-miR-557 0.001621039 DOWN
hsa-miR-1207-5p 0.008294453 DOWN
hsa-miR-874 0.0190089 DOWN
hsa-miR-556-3p 0.045900322 UP
IDC vs. Normal hsa-miR-638 0.001237625 DOWN
hsa-miR-575 0.002705719 DOWN
hsa-let-7f 0.005910912 UP
hsa-miR-671-5p 0.008136721 DOWN
hsa-miR-20a 0.012225322 UP
hsa-miR-15a 0.012381793 UP
hsa-miR-1202 0.014062578 DOWN
hsa-miR-183 0.016907487 UP
hsa-miR-141 0.017054873 UP
hsa-miR-19b 0.021237634 UP
hsa-miR-1915 0.024006981 DOWN
hsa-miR-107 0.02413377 UP
hsa-miR-21 0.024726247 UP
hsa-miR-1274b 0.025880286 UP
hsa-miR-1268 0.027592959 DOWN
hsa-miR-200b 0.028273659 UP
hsa-miR-106b 0.03564651 UP
hsa-miR-634 0.037061296 DOWN
hsa-miR-129* 0.037617348 DOWN
hsa-miR-572 0.04061733 DOWN
hsa-miR-933 0.04227081 DOWN
hsa-miR-17 0.042894967 UP
hsa-miR-29b 0.0460609 UP
hsa-miR-877* 0.04818575 UP
hsa-miR-425 0.048827756 UP
A set of samples diagnosed with Normal, ADH, DCIS, and IDC (4 of each) were
subject to the microarray analysis as we performed for the microdissected
groups. In both paired and un-paired analyses, there were more deregulated
miRNAs during the Normal-ADH transition compared to other processes.
Deregulated miRNAs that appeared in both analyses are bolded.
doi:10.1371/journal.pone.0054213.t002
Deregulated miRNAs in Breast Cancer
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distinct stages of breast cancer are evolutionally associated with the
same origin tumor colony or tumor stem cell within the individual
patient. Therefore the alterations of most miRNA repertories are
inherited from that stem cell and differ from others. Furthermore,
it might also explain the reason why some patients diagnosed with
ADH or DCIS never progress to IDC.
MiRNAs as Potential Molecular Markers for Early Stage
Breast Cancer
Instead of persisting on the existence of a stage specific miRNA
signature of early breast lesion, we started to focus on whether
there will be some individual or combination of unique miRNAs
for each stage. ANOVA test was applied to look for stage specific
deregulated miRNAs with statistical significance (p,=0.05). We
successfully found 35 miRNAs with unique expression in one
certain stage against the others. Another unsupervised hierarchical
clustering based on the identified differentially expressed miRNAs
was generated to determine if they can distinguish between the
different stages of breast lesion. The clustering results indicated the
significantly altered miRNA entities identified by the ANOVA test
distinguished between different stages of breast lesion better than
broad-wide miRNAs. Seven individual clusters were clearly
discerned by the clustering algorithms (Fig. 2). We selected a
short list of miRNAs (miR-644, miR-556-3p, miR-557, miR-141,
miR-183, miR-200b and miR-21) based on both their represen-
Figure 1. Unsupervised clustering results on both miRNAs and conditions of the 23 samples. One solid color box represents a certain
condition. The clustering dendrogram indicates stages from the same patient were more closely clustered than those from the same stages.
doi:10.1371/journal.pone.0054213.g001
Deregulated miRNAs in Breast Cancer
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tation of different clusters for classification on discrete stages, as
well as their higher expression levels and relevance to breast
cancer.
QRT-PCR Verification on Microarray Result
QRT-PCR was performed to verify the miRNAs selected from
the ANOVA test. We first chose miR-16 and let-7a as reference
genes; however, let-7a was used as the sole reference subsequently
since there appeared to be little difference between using both and
using let-7a alone (Supplementary 3). Let-7a showed a compar-
atively consistent and abundant expression level within all the
samples (Fig. 3). One of the identified up-regulated miRNAs, miR-
200b, has been widely reported as a tumor suppressor miRNAs.
To verify this, we also assessed the expression of miR-200c, which
belongs to the same miR-200 family. It is believed that miRNAs
from the same family might have similar expression patterns.
Furthermore, our second unpaired microarray also showed
increased expression levels of miR-200b (data not shown). We
observed that the expression of miR-141, miR-183, miR-200b/c
and miR-21 began to increase during the Normal-ADH transition,
and maintained their high expression profiles during later stages.
Interestingly, low expression of miR-557 was observed in the
DCIS stage (Fig. 4). The correlative expression results from qRT-
PCR analysis were consistent with the expression pattern by
microarray assays. However, miR-644 and miR-556-3p were
hardly detectable by qRT-PCR, as raw Ct values were underneath
the detectable baseline (data not shown). In summary, there seems
to be promising evidence of a group of miRNAs that might have
the potential to distinguish between discrete stages of breast cancer
procession.
Unpaired Analysis of miRNA Microarray Data
To confirm our initial findings, we performed miRNA
microarray expression profiling on the 16 patient samples,
Figure 2. Unsupervised clustering results on ANOVA identified miRNAs and conditions of the 23 samples. Each solid color box
represents a certain condition. The clustering result indicates the significantly altered miRNA entities identified by ANOVA test have more potential to
distinguish different stages of breast cancer than broad-wide miRNAs. Seven individual clusters were clearly discerned by the clustering algorithms
and the miRNAs circled by red rectangles representing their discrete clusters.
doi:10.1371/journal.pone.0054213.g002
Deregulated miRNAs in Breast Cancer
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including 4 normal, 4 ADH, 4 DCIS and 4 IDC. An ANOVA
Benjamin and Hochberg FDR corrected test was performed to
identify stage specific deregulated miRNAs. The expression of 98
miRNAs were identified as significantly altered (p,=0.01) from
this unpaired analysis, of which among them 10 were overlapped
with our previous paired ANOVA analysis (Fig. 5). Therefore the
10 overlapped miRNAs may have significant value in both
diagnosis and management of early breast cancer.
Figure 3. qRT-PCR results displaying the raw Ct values of let-7a across all samples and stages. The profile shows that let-7a expression
was relatively consistent among different components and patients. The error bars indicate that the standard error of mean (SEM) is n = 4.
doi:10.1371/journal.pone.0054213.g003
Figure 4. QRT-PCR verification of miRNAs expression results from microarray data. Blue bars represent the results from microarray, while
red bars indicate the results from qRT-PCR. The error bars are the standard error of mean (SEM) for each analysis. QRT-PCR results are largely
consistent with our microarray data. Five representative miRNAs (miR-21, miR-183, miR-141, and miR-200b/c) were observed up-regulated during the
Normal-ADH transition, and their high expression levels were maintained throughout the tumor developmental stages. miR-557 was found to be
down-regulated specifically in the DCIS stage.
doi:10.1371/journal.pone.0054213.g004
Deregulated miRNAs in Breast Cancer
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Prediction of miRNAs’ Target Genes and Pathway
Analysis
We performed miRNA target prediction as well as their
associated pathway analysis, using the three most common
algorithms: TargetScan Human 6.0 (http://www.targetscan.org),
Diana microT 3.0 (http://diana.cslab.ece.ntua.gr/microT/) and
miRanda (http://www.microrna.org/microrna/home.do). Tar-
gets were regarded as positive only if they were predicted by at
least two algorithms. The ones that were predicted by all three
algorithms were bolded. Target gene lists were subjected to
pathway analysis using GeneSpring GX and IPA (Ingenuity
Pathway Analysis) for potential significant pathway analysis
(Supplementary data 4). Of the identified pathways, the most
significant pathway regulated by miR-21 was the TGF-b pathway.
Target prediction results indicate that miR-21 might promote the
TGF-b pathway by silencing the inhibitor SMAD7. An activated
TGF-b pathway, therefore, can accelerate the generation of
mature miR-21 in a feed-forward loop fashion. The TGF-b
pathway was reported to have both a tumor promoting and
suppressing effect. MiR-21 can debilitate its tumor suppressing
branch by silencing MSH2, one of the DNA mismatch repair
genes [30].
MiR-21 Inhibition in Human Breast Cancer
MiR-21, one of the most reported miRNAs, is involved in the
progression of many cancers. Our study shows during the early
stage of breast lesion, miR-21might function as a major force in
driving tumor progression, due to its continuously high expression
level. TGF-b signaling is well studied for its anti-mitogenic
function during the early stages of cancer, but promotes invasion
and metastasis in later stages. Activated TGF-b pathway can also
induce mature miR-21 expression. In this study, we transfected
anti-miR-21 oligos as well as the scrambled oligo mocks into
human breast cancer cell lines MCF-7 and Hs578T. After
48 hours, with 60%–80% miR-21 knock-down, we observed a
significant restoration of MSH2 and SMAD7 mRNA expression
(Fig. 6A and 6B). The protein level was increased by ,35% in
MCF-7 and,43% in Hs578T for MSH2; and by,80% in MCF-
7 and ,133% in Hs578T for SMAD7 by Western blot analysis
(Fig. 6C). These findings indicate that overexpression of miR-21
might activate TGF-b signaling by suppressing SMAD7, which
functions as an inhibitory SMAD protein in TGF-b signaling.
Silencing TGF-b signaling may in turn induce the expression of
tumor suppressor genes, such as MSH2.
Discussion
In this study, we investigated miRNA expression profiling along
the linear ductal breast cancer procession model, Normal-ADH-
DCIS-IDC, using laser capture microdissected FFPE tissues. The
following comparisons were done: ADH vs. Normal, DCIS vs.
Normal, and IDC vs. Normal. Analysis revealed that there were
more miRNA alterations in the transition between Normal to
ADH, suggesting that miRNAs possess a significant role in early
tumor initiation; the expression deregulation seems to be
maintained throughout DCIS and IDC. These findings agree
with previously reported mRNA microarray profiling, which
showed that the most prominent transcriptional changes take place
at the Normal and ADH stages and such types of alterations could
be maintained throughout the later stages [29].
We were unable to readily identify miRNAs that could
distinguish between different subgroups at the pre-invasive stages
ADH and DCIS, or the invasive stage IDC, as most of the
significant alterations of the miRNAs occurred during the normal-
ADH transition. These findings might challenge us to rethink our
current research viewpoint on the pre-invasive to invasive ductal
carcinoma progression. Research on the transition between DCIS
to IDC seems to overvalue the focal ductal component, in which
selective subpopulations of neoplastic DCIS epithelial cells
accumulate with serial genetic alterations and corresponding
abilities to disrupt the epithelial layers and then invade from the
basement membrane to the surrounding stromal tissues [31] [32].
However, the changes in the microenvironment between DCIS
and IDC, in other words, the adjacent non-neoplastic epithelial
cells and stromal cells respectively, collaboratively govern a tumor
micro-environmental signaling interaction that facilitates the
transition from pre-invasive to invasive status. Taken together,
the number of ductal carcinoma gene aberrant alteration could
not be the only attributor to the DCIS-IDC transition. Without
taking the adjacent micro-environment into account, it would be
difficult to define the genetic differences between each stage.
Nevertheless, we did identify a candidate miRNA, miR-554,
which shows a relatively lower expression level exclusively in DCIS
stage. This miRNA was identified as significantly altered from
both paired and unpaired analysis. This indicates that miR-554
could be a unique miRNA marker for DCIS.
In this study, we also observed one of the currently well studied
tumor-suppressor miRNAs, miR-200b, as well as miR-200c from
the same family, which showed increased expression throughout
all stages. MiR-200b was first reported to directly target E-
cadherin repressors ZEB1 and ZEB2 and thus inhibit epithelial-
mesenchymal-transition (EMT) in cell line models [33–35].
Additional studies show that over-expression of miR-200b/c is
able to trigger mesenchymal-epithelial-transition (MET) of meta-
plastic breast cancer [33]. Ardent investigation and flux of newly
published papers suggest that miR-200 families impact cancer
invasiveness by collaborating with other molecules, such as Notch
[36], Twist1 [37] and PLCc1 [38]. However, concomitant
expression of EMT biomarkers in DCIS compared to IDC
revealed that biomarkers including E-cadherin, b-catenin and
Snail did not show any statistical significantly positive or negative
correlation, except for TGF-b1 and c-Met [39]. On the other
hand, miR-200c up-regulation was reported to inhibit pancreatic
cancer invasion but increase cell proliferation [26]. This indicates
that proliferation is one of the most essential phenotypes of
neoplastic cells during the pre-invasive stage. To the best of our
knowledge, down-regulation of miR-200 family rein on the tumor
precession was not observed in all breast cancer cell lines. For
instance, a study in isogenic mouse breast cancer cells indicated
Figure 5. Venn diagram of ANOVA test results from paired and
unpaired miRNA expression analysis. ANOVA test on the paired
miRNA microarray data analysis resulted in 35 deregulated miRNAs,
while ANOVA test on the unpaired analysis showed 98 deregulated
miRNAs. There are 10 overlapping miRNAs (miR-1268, mir-130a, miR-
141, miR-193b, miR-200b, miR-21, miR-320a, miR-370, miR-557 and
kshv-mir-K12-3).
doi:10.1371/journal.pone.0054213.g005
Deregulated miRNAs in Breast Cancer
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that miR-200 members enhance cell colonization to form distant
metastases [40]. Additionally, miR-200c was actually observed to
be up-regulated to stimulate proliferation in human pancreatic
cancer [26]. The function of miR-200 family remains to be
elucidated in pre-invasive breast cancer.
Similarly, another well studied miRNA, miR-21 was observed
to have displayed an increasing expression trend during breast
cancer progression. Target prediction and pathway analysis on the
potential downstream targets of miR-21 indicated that miR-21
might promote tumor progression by targeting the TGF-b
pathway. MiR-21 can regulate the TGF-b pathway by silencing
its inhibitors, such as SMAD7. An up-regulated TGF-b pathway
can expedite the generation of mature miR-21 in a feed-forward
manner [41,42]. The nature of TGF-b signaling is controversial,
as it can play both a tumor suppressive role by inhibiting cell
proliferation and inducing apoptosis in normal epithelial cells, as
well as a more aggressive role by promoting tumor growth and
invasion. Active TGF-b pathway correlates with poor prognostic
and survival rates of breast cancer in the clinic, while suppression
of the TGF-b pathway is also reported to be lethal for mice.
Therefore it is important to develop strategies to selectively block
the cancer-promoting branch but maintain the anti-mitogenic
branch of the TGF-b pathway for developing therapeutic drugs. It
was recently reported that miR-21 mediates TGF-b bidirectional
regulation on MSH2, a central component of DNA mismatch
repair (MMR), to contribute chemo-resistance in breast cancer
[30]. In the normal cells with intact p53 function and a lower level
of miR-21, TGF-b predominantly promotes MSH2 expression,
contributing to DNA repair and maintenance of genomic stability.
On the other hand, overexpression of miR-21 is often coupled
with p53 inactivation in cancerous context, and silences MSH2 by
directly binding on its 39-UTR, resulting in genomic instability
and resistance to DNA-damaging chemotherapy agents. MiR-21
Figure 6. Knockdown of miR-21 restores the expression of SMAD7 and MSH2 in MCF-7 and Hs578T breast cancer cell lines. MCF-7
and Hs578T cells were transfected with miR-21 inhibitor and a negative mock control using the Lipofectamine 2000 kit (Invitrogen). After 48 hrs, miR-
21 expression level was knocked down by,10 fold as compared to the mock controls in both MCF-7 (Fig. 6A) and Hs578T (Fig. 6B) cell lines using the
Invitrogen SYBR green qRT-PCR kit. Untransfected cells were also included in the analysis (WT). With down-regulated miR-21 in both MCF-7 and
Hs578T cells, MSH2 and SMAD7 mRNA expression was up-regulated by,1.67 and,3.6 fold, respectively (Fig. 6A and 6B), while the protein level was
increased by ,35–43% for MSH2 and ,80–133% for SMAD7 (Fig. 6C).
doi:10.1371/journal.pone.0054213.g006
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might be a mediator for the TGF-b pathway and thus can be a
potential target for breast cancer therapy.
In conclusion, deregulation of miRNA expression during
tumorigenesis might be an early event as it occurs significantly
during normal to ADH transition. Target prediction and pathway
analysis revealed that miR-21 has a pivotal role on selective
utilization of the TGF-b pathway in breast cancer initiation.
Importantly, we have demonstrated the feasibility of miRNA
expression profiling analysis using archived FFPE tissues, rich with
clinical information, as a means towards miRNA biomarker
discovery.
Materials and Methods
FFPE Tissue Breast Cancer Samples and Laser Capture
Microdissection
A total of 24 female patient breast tissue samples in FFPE from
our previous studies [43] were used in this study. Tissue blocks
were retrieved from the tissue repository of the Armed Forces
Institute of Pathology with IRB approved protocols. Among them,
eight were subject to microdissection, resulting in 23 usable tissue
components, including normal, hyperplasia, DCIS, and IDC.
Different tissue components were separately microdissected from
selected cases as described previously [43]. The other 16 FFPE
samples with definitive clinical diagnosis of breast lesions were
identified, and a total of 4 pieces of 20 mm thick FFPE sections
were cut from each case and collected in a 1.5 ml tube.
RNA Extraction from FFPE Tissue
RecoverAllTM Total Nucleic Acid Isolation Kit for FFPE
Tissues (Ambion, Austin, TX) was applied to nucleic acid isolation
according to the optimized protocol [44]. Briefly, 1 ml of xylene
was added into the 4 pieces of 20 mm thick FFPE sections to
remove traces of paraffin. The tissues were digested with protease
K at 50uC overnight and treated with DNase I. After washing,
total RNA, including a small miRNA fraction, was eluted with
distilled water. RNA concentration was measured using the
Nanodrop spectrophotometer. The RNA integrity number (RIN)
was assessed with an Agilent 2100 Bioanalyzer using the RNA
6000 LabChip kit (Agilent, Palo Alto, CA).
miRNA Microarray Assay
The Agilent Human MicroRNA Microarray V3 Technology
platform was used, which contains 866 mature human miRNAs
and 86 viral miRNAs according to the vendor’s protocol. Total
RNA (100 ng) was dephosphorylated via 37uC incubation with
phosphatase for 30 min. The dephosphorylated RNA was mixed
with 2.8 ml of 100% DMSO, and then heated at 100uC for 7 min
and immediately cooled on an ice water bath. Labeling reactions
were carried out and samples incubated at 16uC for 2 hr. Labeled
RNA samples were dried in a speed vacuum at 55uC for 3 hours.
Samples were then reconstituted and mixed with a hybridization
cocktail followed by a 5 min 100uC incubation, and then it was
immediately transferred to the ice water bath for 5 min. With
samples loaded, hybridization chambers were ensconced in the
hybridization oven and incubated at 50uC and a 20 rpm rotation
for 20 hr. After hybridization, slides were removed from the
chambers and submerged in the provided GE Wash Buffer 1, and
washed as follows: GE wash buffer 1 (2 ml 10% Triton X-102
added into 4 L wash buffer) at room temperature for 5 min, and
overnight pre-warmed GE Wash Buffer 2 at 37uC for 5 min.
Slides were briefly dried and scanned by Agilent’s High-Resolution
C Scanner.
Feature Extraction and Pre-processing of miRNA
Microarray Data
Probe level data was extracted from the microarray image by
using the Agilent Feature Extraction Software (v10.5). QC reports
were automatically generated for each array. All the raw data from
Feature Extraction were logarithmically transformed to base 2,
with quantile algorithm normalization as described [45].
Statistical Analysis
For the microdissected samples, paired t-test as well as one-way
ANOVA were performed to investigate significantly altered
miRNAs of one stage against the other three. Deregulated
miRNAs were considered as significant if p,=0.05. For the
second set of samples, an unpaired t-test as well as one-way
ANOVA (Benjamin and Hochberg FDR correction) were
performed to identify miRNAs that were changed significantly
when comparing one stage against the other three. Each identified
miRNA was considered as significant if p,=0.01. A Venn
diagram was drawn to show the overlap of miRNAs between the
two analyses.
Hierarchical Clustering Analysis
Unsupervised hierarchical clustering on sample conditions with
all detected miRNA entities was generated by Genespring GX
11.5 clustering analysis (Agilent). Euclid distance algorithms were
applied for clustering. The unsupervised hierarchical clustering on
sample conditions with the most significantly altered miRNA
entities was generated in the same manner, while the most
significantly altered miRNAs were generated by ANOVA test on
all the samples, and filtered by their expression level based on raw
data (50th percentile–100th percentile).
TaqMan miRNA qRT-PCR Analysis
The RT reaction mixture included 10 ng of total RNA as the
template, 3 ml 5X RT primer, 1.5 ml 10XRT buffer, 0.15 ml of
100 mM dNTPs, 1 ml of MultiScribe reverse transcriptase, 0.19 ml
RNase inhibitor, and 4.16 ml nuclease-free water. The 15 ml
reactions were incubated on an ABI 2720 thermal cycler for
30 min at 60uC, 30 min at 42uC, 5 min at 85uC and then held at
4uC. qRT-PCR was performed on an ABI 7300 real-time PCR
system. The cocktail of 1.5 ml of 1:1 diluted RT product, 10 ml
Taqman Universal PCR Master Mix with No AmpErase UNG,
7.5 nuclease-free water and 1 ml of 20X MicroRNA Assay were
mixed well in an 8-well optical stripe tube, and then incubated
according to the following program: 95uC for 10 min, 95uC for
15 sec repeated for 40 cycles, and 60uC for 1 min. All assays were
repeated in duplicate with nuclease-free water as the no template
control. Relative miRNA expression levels were compared via the
22DDCt method [46]. To normalize the qPCR results, let-7a was
chosen as the reference gene based on its high and consistent
expression.
Target Prediction and Pathway Analysis
Downstream targets of the significantly changed miRNAs were
predicted using three different algorithms, specifically TargetScan
6.0, Diana microT 3.0 and miRanda (microrna.org). Each Target
was regarded as positive only if it was predicted by at least two of
the three algorithms. A list of candidate target genes was subjected
to GeneSpring GX or IPA (Ingenuity Pathway Analysis) analysis.
Anti-miR-21 oligo Transfection
Anti-miR-21 and scrambled mock oligos were purchased from
Ambion. On the day of transfection, a total of 240,000 cells were
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seeded in each well of a 6-well plate. Dilutions of 90 pmol of oligos
or mocks and 5 ml of Lipofectamine 2000 (Invitrogen) in 250 ml
OptiMEM serum free medium (Invitrogen) were prepared and
incubated at room temperature for 20 min. The 500 ml mixture
was applied to each well of the 6-well plate. The cells were
cultured on antibiotic-free DMEM medium with 10% FBS at a
total volume of 3 ml. Cells were harvested after 48 hrs and the
miRNAs were isolated using the mirVana miRNA isolation kit
(Ambion).
Western Blot Analysis
The Western blot experiment was performed as described
previously [47]. Cell protein lysates were prepared with SDS gel-
loading buffer containing b-mercaptoethanol and heated at 95uC
for 5 minutes. Proteins were separated by SDS-PAGE using a
12% Mini-PRPTEAN TGX gel (Bio-Rad) and transferred for
2 hours at 100 V. The membrane was blocked prior to the
addition of the primary antibody with 5% milk in Tris-buffered
saline (TBS) with 0.05% Tween. The membrane was incubated
overnight with either MSH2 rabbit polyclonal antibody (Cat#
AP11570c, Cell Signaling) at a dilution of 1:500 in TBS buffer
with 0.05% Tween and 5% milk, SMAD7 rabbit polyclonal
antibody (Cat# AP6753c, Cell Signaling), at a dilution of 1:200 in
TBS buffer with 0.05% Tween and 5% milk, or GAPDH mouse
monoclonal antibody (Cat# MA5-15738, Sigma) at a dilution of
1:1,000 in TBS buffer with 0.05% Tween. The membrane was
washed 3 times with TBS/0.05% Tween and incubated with an
anti-rabbit IgG conjugated to horse radish peroxidase (Cat#
7074S, Cell Signaling) for MSH2 and SMAD7, and an anti-mouse
IgG (Cat# 7076S, Cell Signaling) for GAPDH at a 1:1,000
dilution in TBS/0.05% Tween (and 5% milk). Super Signal West
Femo Maximum Sensitivity Substrate (Thermo) was used accord-
ing to the manufacturer’s protocol to visualize proteins and
quantify band intensity.
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